Bastiaan Jeroen van der Baan - 26 Sep 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
President and CEO, Director
Signature
/s/ Bastiaan van der Baan
Issuer symbol
LIXT
Transactions as of
26 Sep 2023
Net transactions value
$0
Form type
4
Filing time
27 Sep 2023, 06:05:59 UTC
Previous filing
07 Jul 2023
Next filing
05 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +250,000 $0.000000 250,000 26 Sep 2023 Common 250,000 $1.95 Direct F1
transaction LIXT Options to Purchase Common Stock Award $0 +10,000 $0.000000 10,000 30 Jun 2023 Common 10,000 $5.88 Direct
transaction LIXT Options to Purchase Common Stock Award $0 +25,000 $0.000000 25,000 17 Jun 2022 Common 25,000 $7.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested.

Remarks:

NOTE: Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of common stock set forth above for all transactions entered into prior to that date have been adjusted to reflect the reverse stock split.